Get Help Now
Elmiron Vision Loss Lawsuit
How Elmiron Causes Vision Loss: Retinal Pigment Epithelium Toxicity
In Plain Language
Elmiron (pentosan polysulfate sodium, or PPS) was approved by the FDA in 1996 as the only oral medication for interstitial cystitis (IC), a chronic and painful bladder condition that disproportionately affects women — approximately 90% of IC patients are female. For 22 years, Elmiron was prescribed without any warning about potential vision damage. In 2018, researchers at Emory University published the first clinical report linking long-term Elmiron use to a novel form of drug-induced maculopathy — progressive damage to the retinal pigment epithelium (RPE) and photoreceptor layer that mimics age-related macular degeneration (AMD) but has a distinct pattern on retinal imaging. The Elmiron-associated maculopathy is dose-dependent and cumulative, meaning patients who take the drug for longer periods at standard doses face increasing risk of irreversible central vision loss. Many patients were misdiagnosed with AMD or pattern dystrophy for years before the Elmiron connection was identified.
Retinal Pigment Epithelium Toxicity
Pentosan polysulfate sodium accumulates in the retinal pigment epithelium (RPE) — the critical cell layer that supports photoreceptor health by recycling visual pigments, removing metabolic waste, and maintaining the blood-retina barrier. PPS disrupts RPE cellular function through mechanisms that likely involve interference with lysosomal processing and impairment of the phagocytic cycle by which RPE cells digest shed photoreceptor outer segments. As RPE cells become dysfunctional and die, the overlying photoreceptors lose their metabolic support and degenerate. The damage is concentrated in the macula — the central region of the retina responsible for sharp, detailed vision — producing the characteristic pigmentary maculopathy seen on fundoscopic examination.
Photoreceptor Degeneration and Central Vision Loss
Once the RPE is damaged by PPS accumulation, the overlying cone and rod photoreceptors undergo secondary degeneration. Cones — concentrated in the fovea and responsible for color vision and fine detail — are particularly vulnerable because foveal cones depend entirely on RPE support for their extraordinarily high metabolic demands. Patients with Elmiron maculopathy typically present with difficulty reading, problems adapting to dim lighting (nyctalopia), and metamorphopsia (distortion of straight lines). Optical coherence tomography (OCT) reveals thinning of the outer retinal layers and disruption of the ellipsoid zone, confirming photoreceptor loss. Critically, photoreceptor loss in the human retina is irreversible — once these cells are destroyed, vision cannot be restored.
Dose-Dependent and Cumulative Toxicity
The risk of Elmiron-associated maculopathy increases with cumulative drug exposure. Studies have shown that patients with more than three years of PPS use have significantly higher rates of macular changes compared to shorter-duration users. The Emory group's initial 2018 report found that six of six patients in their series had been taking Elmiron for 15 years or more. Subsequent population-level studies have estimated that the prevalence of pigmentary maculopathy increases from approximately 10% at 5 years of use to over 20% at 10+ years. This dose-response relationship is a hallmark of drug toxicity and strongly supports a causal link between PPS and retinal damage.
Progressive Damage After Drug Discontinuation
One of the most troubling features of Elmiron maculopathy is that retinal damage can continue to progress even after the drug is discontinued. Multiple case reports and clinical series have documented worsening macular changes and continued vision decline in patients who stopped taking Elmiron months or years earlier. This progressive course suggests that PPS accumulation in the RPE triggers a self-sustaining cycle of cellular dysfunction and death that persists beyond active drug exposure. For patients who took Elmiron for decades without vision monitoring, significant irreversible damage may have already been established by the time the drug is stopped.
Danger Factors
- 22 Years Without Vision Warning: Elmiron was sold from 1996 to 2018 without any warning about potential retinal toxicity. During this period, millions of prescriptions were filled for a predominantly female patient population that had no reason to suspect their bladder medication was damaging their eyesight.
- Misdiagnosis as Age-Related Macular Degeneration: Because Elmiron maculopathy mimics the appearance of AMD on standard fundoscopic examination, many patients were misdiagnosed with AMD for years. The misdiagnosis delayed recognition of the drug as the cause, resulting in continued Elmiron use and further retinal damage.
- Only Oral IC Medication: Elmiron was the only FDA-approved oral medication for interstitial cystitis, giving patients and prescribers limited alternatives. Many patients continued Elmiron despite mild visual symptoms because no comparable substitute was available.
- Irreversible Central Vision Loss: The retinal damage caused by Elmiron affects the macula — the area responsible for reading, driving, and recognizing faces. Unlike peripheral vision loss, macular damage strikes at the core of functional independence.
Scientific Consensus
- The 2018 Emory University study by Dr. Nieraj Jain and colleagues was the first to identify a novel pigmentary maculopathy associated with long-term Elmiron use, published in Ophthalmology
- The FDA updated the Elmiron label in June 2020 to include warnings about retinal pigment changes and recommended baseline and periodic eye examinations
- Population-level studies have confirmed a dose-response relationship, with maculopathy prevalence increasing with cumulative PPS exposure duration
- The American Urogynecologic Society has acknowledged the Elmiron-vision risk and supports ophthalmologic screening for long-term users
- Multiple retinal imaging studies have defined a characteristic pattern of Elmiron maculopathy on OCT and fundus autofluorescence that is distinguishable from typical AMD by experienced retinal specialists
Why This Matters for Your Case
The Elmiron vision loss litigation alleges that Janssen Pharmaceuticals (a Johnson & Johnson subsidiary) knew or should have known about the risk of retinal toxicity and failed to warn prescribers and patients for over two decades. The fact that the drug was the only oral IC medication — prescribed overwhelmingly to women — and that the resulting macular damage is irreversible, makes this litigation particularly compelling. Patients who took Elmiron for years or decades without any recommendation for eye monitoring now face permanent central vision loss that could have been detected early and potentially limited by drug discontinuation.
Did you experience vision problems after taking Elmiron for bladder pain? Get a free case evaluation today.
Get Your Free Case Reviewor call 1-800-555-0100
Internal Documents & Evidence
Jain et al. 2018: Discovery of Elmiron-Associated Pigmentary Maculopathy
“Dr. Nieraj Jain and colleagues at Emory Eye Center identified a novel pattern of pigmentary maculopathy in six patients with long-term Elmiron use (all had taken the drug for 15+ years). Using fundus autofluorescence imaging and OCT, the researchers described a distinctive pattern of paracentral RPE atrophy and photoreceptor loss that was different from typical age-related macular degeneration. This was the first report in the medical literature linking Elmiron to retinal toxicity — a connection that had gone undetected for 22 years despite millions of prescriptions. The discovery prompted a retrospective review that identified additional cases among IC patients previously misdiagnosed with AMD or pattern dystrophy.”
Impact: The Jain discovery is the foundational scientific evidence in the Elmiron litigation. It established that a drug prescribed for 22 years without vision warnings was causing a specific, identifiable pattern of retinal damage. The fact that the maculopathy had been misdiagnosed as AMD in multiple patients for years before the Emory publication demonstrates that without specific awareness of the Elmiron connection, the drug-induced nature of the maculopathy was not being recognized — underscoring the critical importance of label warnings and ophthalmologic monitoring recommendations.
Population-Level Studies Confirming Dose-Response Relationship
“Following the 2018 Emory discovery, multiple research groups conducted population-level studies of Elmiron users using electronic health records and retinal imaging databases. These studies consistently confirmed a dose-response relationship: the prevalence of pigmentary maculopathy increased with cumulative duration of Elmiron use. Studies from Kaiser Permanente estimated maculopathy rates of approximately 10% at 5 years of use, rising to 20% or more at 10+ years. The dose-response relationship was consistent across geographic regions, patient demographics, and imaging modalities, providing strong epidemiological evidence of a causal association. Some studies also documented continued progression of retinal changes after drug discontinuation.”
Impact: The dose-response data is critical to establishing general causation in the Elmiron litigation. A consistent dose-response relationship is one of the Bradford Hill criteria for causal inference in epidemiology and significantly strengthens the argument that Elmiron causes — rather than merely correlates with — macular damage. For litigation purposes, the dose-response data also supports claims that longer-term users, who had the most cumulative exposure without any warning to obtain eye monitoring, suffered the greatest harm.
Misdiagnosis as Age-Related Macular Degeneration: Years of Delayed Recognition
“Following the 2018 Emory publication, retrospective reviews at multiple academic medical centers identified Elmiron patients who had been diagnosed with age-related macular degeneration, pattern dystrophy, or idiopathic pigmentary maculopathy years before the Elmiron connection was recognized. In some cases, patients had been receiving anti-VEGF injections for presumed AMD while continuing to take Elmiron — the very drug causing their retinal damage. The misdiagnosis occurred because, without awareness of the Elmiron association, ophthalmologists attributed the macular findings to the most common known conditions with similar appearances. The misdiagnosis pattern demonstrates that Elmiron maculopathy was hiding in the medical system for years, affecting patients who were not being correctly diagnosed because the manufacturer had never warned of the risk.”
Impact: The misdiagnosis evidence is powerful in the Elmiron litigation because it demonstrates the real-world consequences of the 24-year labeling failure. Patients were not only unwarned about vision risk — they were actively misdiagnosed with other conditions because the medical community had no reason to suspect their bladder medication. Each misdiagnosed patient continued taking Elmiron, accumulating further retinal damage, when discontinuation at the first sign of maculopathy might have limited or halted the progression of vision loss.
Did you experience vision problems after taking Elmiron for bladder pain? Get a free case evaluation today.
Get Your Free Case Reviewor call 1-800-555-0100
Regulatory History of Elmiron: 24 Years of Silence on Vision Risk
Elmiron's regulatory history is defined by a 24-year gap between FDA approval and the first label warning about retinal toxicity. Approved in 1996 for interstitial cystitis with no eye-related warnings, Elmiron was prescribed to millions of patients — predominantly women — before the 2018 Emory University discovery triggered regulatory action. The FDA's June 2020 label update, while acknowledging the risk, came after more than two decades of unwarned exposure.
FDA approved Elmiron (pentosan polysulfate sodium) as the first and only oral medication for interstitial cystitis. The prescribing information contained no warnings about retinal toxicity, maculopathy, or any vision-related adverse effects. The clinical trials used to support approval did not include ophthalmologic monitoring or retinal imaging as part of the safety assessment protocol.
Dr. Nieraj Jain and colleagues at Emory University published 'Maculopathy Associated With Exposure to Pentosan Polysulfate Sodium' in Ophthalmology, the journal of the American Academy of Ophthalmology. The paper described six patients with a novel pattern of pigmentary maculopathy linked to long-term Elmiron use. All six patients had taken Elmiron for 15 or more years. The maculopathy was characterized by a distinctive pattern of paracentral RPE damage visible on fundus autofluorescence imaging that was distinguishable from typical AMD. This was the first identification of Elmiron as a retinal toxin.
The FDA required Janssen Pharmaceuticals to update the Elmiron prescribing information to include warnings about retinal pigmentary changes. The revised label recommended baseline and periodic retinal examinations during treatment and advised prescribers to weigh the benefits of treatment against the potential risk of retinal toxicity. The update came nearly 24 years after the drug's original approval and more than 18 months after the Emory study was published.
Following the 2018 Emory publication, the FDA's adverse event reporting systems received a surge of reports from ophthalmologists and patients describing macular changes consistent with PPS toxicity. Many reports described patients who had been previously diagnosed with AMD or pattern dystrophy and were reclassified as having Elmiron-associated maculopathy after the Emory findings were publicized. The volume of retrospective reclassifications suggested that the true prevalence of Elmiron maculopathy was substantially higher than initially recognized.
The American Urogynecologic Society issued guidance acknowledging the association between long-term Elmiron use and retinal changes. The guidance recommended that urogynecologists discuss the potential vision risk with patients before prescribing Elmiron, consider alternative treatments when appropriate, and refer long-term Elmiron users for comprehensive ophthalmologic evaluation including OCT and fundus autofluorescence imaging.
Significance Legend
Key Takeaway
Elmiron was sold for 24 years as the sole oral treatment for interstitial cystitis with absolutely no warning about retinal toxicity. The 2018 discovery by Emory researchers revealed a novel drug-induced maculopathy that had been hiding in plain sight — misdiagnosed as AMD in countless patients. The FDA's June 2020 label update, while necessary, came decades too late for patients who had already sustained irreversible macular damage.
Janssen and J&J: 24 Years of Elmiron Sales Without Vision Warnings
Elmiron has been manufactured and marketed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, since its 1996 FDA approval. As the only FDA-approved oral treatment for interstitial cystitis — a chronic condition affecting an estimated 3 to 8 million Americans, approximately 90% of whom are women — Elmiron occupied a monopoly position in its therapeutic category. The drug generated steady revenue for Janssen over more than two decades, during which no vision-related warnings appeared on the label. The 2018 discovery of Elmiron-associated maculopathy by Emory University researchers and the subsequent litigation represent a significant product liability exposure for J&J, which has faced criticism for its failure to conduct post-market ophthalmologic surveillance despite the drug's long-term chronic use profile.
Timeline: Janssen Pharmaceuticals (Johnson & Johnson subsidiary)
Did you experience vision problems after taking Elmiron for bladder pain? Get a free case evaluation today.
Get Your Free Case Reviewor call 1-800-555-0100